Improving vaccine delivery using novel adjuvant systems

 Abstract

Adjuvants have been common additions to vaccines to help facilitate vaccine delivery. With advancements in vaccine technology, several adjuvants which activate immune specific responses have emerged. Available data show these adjuvants elicit important immune responses in both healthy and immunocompromised populations, as well as the elderly. Guidelines for the use and licensure of vaccine adjuvants remain under discussion. However, there is a greater understanding of the innate and adaptive immune response, and the realization of the need for immune specific adjuvants appears to be growing.

This is a focused review of four adjuvants currently in clinical trial development: ASO4, ASO2A, CPG 7907, and GM-CSF. The vaccines including these adjuvants are highly relevant today, and are expected to reduce the disease burden of cervical cancer, hepatitis B, and malaria.

Full Text Options
Article
Metrics
 Share
 Full Text
 Info
Pages
262 - 270
doi
10.4161/hv.4.4.5742
Type
Review
 Metrics
 Cite This Article
 Permissions
 Permissions
 Reprints
Improving vaccine delivery using novel adjuvant systems